Bispecific Antibody Therapy Achieves Complete Response in Relapsed Multiple Myeloma: Phase III Results
Rodriguez M, Chen L, et al.View Paper →
SUMMARY
Phase III trial demonstrates 71% overall response rate with bispecific T-cell engager in relapsed/refractory myeloma patients who failed 3+ prior lines. Median PFS of 11.8 months significantly outperformed standard of care.
"Discuss with Dr. Patel for our myeloma protocol update"
SGLT2 Inhibitor vs. Standard Care in HFpEF with Renal Impairment: PRESERVE-HF Trial
AstraZenecaView Trial →
Generate Summary
NeurologyPreprintmedRxivOA2026-04-12
Blood-Based Biomarker Panel Detects Alzheimer's Pathology 8 Years Before Clinical Onset
Nakamura T, Palmqvist S, et al.View Preprint →
CardiologyPubMedThe Lancet12 cited2026-04-11
AI-Guided Echocardiography Improves Detection of Subclinical LV Dysfunction in Primary Care
Wang X, O'Brien K, et al.View Paper →
SUMMARY
AI-assisted echo interpretation in 12 primary care clinics detected subclinical LVSD in 8.2% of asymptomatic patients vs 2.1% with standard assessment, enabling earlier cardiology referral and intervention.
📅 DEADLINES
RSNA Abstract21d
ASCO Meeting51d
ESC Congress136d
AHA Sessions213d
✉ INBOX
dailyweeklyoff
Specialties
26 specialties. 100+ subspecialties.
Pick your specialty, then refine by subspecialty or imaging mode. Your feed, your way.